Pulmatrix (NASDAQ:PULM) Shares Cross Below 50 Day Moving Average – Here’s Why

Posted by Chris Copeland on May 28th, 2026

Pulmatrix, Inc. (NASDAQ:PULM – Get Free Report) shares passed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $1.43 and traded as low as $1.31. Pulmatrix shares last traded at $1.36, with a volume of 14,367 shares trading hands.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulmatrix in a research report on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has a consensus rating of “Sell”.

Get Our Latest Research Report on PULM

Pulmatrix Stock Performance

The firm has a market capitalization of $4.96 million, a P/E ratio of -1.11 and a beta of 1.94. The company has a 50-day moving average price of $1.43 and a 200-day moving average price of $2.51.

Pulmatrix (NASDAQ:PULM – Get Free Report) last posted its quarterly earnings results on Friday, May 15th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Pulmatrix

A hedge fund recently bought a new stake in Pulmatrix stock. DRW Securities LLC purchased a new position in shares of Pulmatrix, Inc. (NASDAQ:PULM – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 20,505 shares of the biotechnology company’s stock, valued at approximately $46,000. 11.84% of the stock is currently owned by hedge funds and other institutional investors.

About Pulmatrix

(Get Free Report)

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).